The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You know who buying again this afternoon ahead of next Tuesday`s results.
Could surprise us all and announce they've had a bid approach from our friend Kight. Before anyone gets too excited I can't see it much above 8.25p. Failing that, it will be the usual cash burn rate and how super excited they are about future prospects.
Good movement this afternoon …
Good News Today …
Let’s see where we go from here
0
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma.
.....
5. Conclusions
In this work, we used in vitro and in vivo experimental models to assess the therapeutic potential of SFX-01 for GBM treatment. Our data suggest that SFN targets ER stress and NRF2, paying as a “master regulator” of the body’s stress response. Secondary but very important effects are the inhibition of HDAC activity especially on class I HDACs and inhibition of STAT3 with reduced activity of NFKB pathways which modulate progression of GBM and induce ROS. So, metabolic, oxidative, and epigenetic modifications are the bases of the different effects of SFN. Our study provided detailed evidence that SFX-01 induced cell death and inhibited the growth of GBM cells and xenografts through the modulation of multiple cell-signaling pathways, demonstrating its potential as a new compound for GBM treatment. SFX-01 was also highly effective in eliminating GSCs through the induction of cell differentiation, compared to the less-malignant astrocyte phenotype. SFX-01 also reduced the vasculogenic properties of GBM cells, thus inhibiting the growth of GBM xenografts in vivo. SFX-01 triggered DNA damage and increased RT-mediated ?-H2Ax expression through the production of ROS. Overall, our preclinical data indicated that the effects of SFX-01 are due to multiple molecular mechanisms, participating in switching off autophagy and switching on apoptosis, which are responsible for SFX-01-mediated cell death.
https://www.mdpi.com/1424-8247/14/11/1082/htm
Now we know why it moved up!
Needed news and will be Interesting to see if the potential of EVG is picked up here today.
"In both models, SFX-01 reduced tumour growth substantially and demonstrated statistically significant improved survival. The in vitro work was complemented by a recent pre-print publication from a different laboratory, the University of Auckland, New Zealand, in patient derived cells and 3D spheroid models of GBM (Leung et al 2021)."
A very encouraging bit of news, hopefully we might see a "substantially" improved sp by cease trading today.
Holding tight …
Unusual for EVG to move up like this , let’s wait and see
Up 10% and hardly any to buy, hold on to what you have don't let them go cheaply.
Ontarget up 9% so perhaps more than two players but who cares as long as this keeps going.
Not only Kight. I know at least two others who have bought over the last few days.
Seems to be gobbling up any shares under 6p
The impatients are feeding him well for Xmas ?
This share is starting to smell like over cooked Broccoli.....
We need some good news to blow away that smell and at least produce some upward movement.
Absolutely, accumulating steadily and the SP has barely moved.
Kight added another 1% https://www.lse.co.uk/rns/EVG/holdings-in-company-eftx5foewuvh6vt.html
Stealthy!
Never caught anything fishing for years.
Went to Homer, Alaska. They have boats that take you out.
They even bait the line for you. You get a 3 foot halibut in no time at all.
It's almost like a diver is down there hooking the fish for you.
Limit of two fish per customer, though.
Waiting for a big halibut.
https://www.peninsulaclarion.com/news/homer-chamber-of-commerce-ends-halibut-derby/
So so quiet …waiting patiently :-)
Zzzzzzz.....show me the money! I have been waiting here patiently for news and hopefully a spike in the sp. One can trade on sp movement but not when it is plodding along within a range.
Getting closer to his buying point.
I did say it would be back down here.
We're currently priced about £5m above cash level so based on that the market certainly agrees with you.
But you also have to bear in mind the general market as a whole has been very poor for at least 2 months too.
If Huw can keep the newsflow coming on glioma as planned, with the pre-IND meeting next (hopefully first half of Q4) followed by IND submission, and with an improving market generally I think interest will start to pick up and the value might start to anticipate some of the potential. With Kight picking up a large part of the already tight free float then it's not going to take much.
In my opinion I don't think there is any confidence that SFX01 works even after a positive phase 2 trial although there are definitely encouraging signs with all the recent studies. I think that is why we sit on a pittance of a market cap. We need to definitely prove our mettle further before we perhaps can come a bit more on the radar of large pharmas. Not saying it can't or won't happen, but my belief is that the probability is low at least now until we get some success in one of the planned trials next year. I would be over the moon of course if something does come to fruition early.
Old news but …
https://thehealthcaretechnologyreport.com/vividion-acquired-by-bayer-to-boost-drug-discovery-platform/
Should be good for EVG ?
Encouraging for the future …
Let’s see where we go from here
Interesting and encouraging but until the drug is at Phase 3 as a treatment for a specific cancer then the sp unlikely to roar away. Holding and hoping.